Managed Care Calendar
- AAPM 2010 Clinical Meeting
Poll
THE BURDEN OF PARKINSON’S DISEASE AND THE NEED FOR EARLY DIAGNOSIS AND EARLY TREATMENT

Parkinson’s disease (PD) is a progressive and disabling neurologic disorder. The disease is the most prevalent type of parkinsonism, a clinical syndrome caused by lesions in the basal ganglia, predominantly in the substantia nigra, which produces deficits in motor behavior. PD occurs when certain neurons in the substantia nigra die or become impaired. See Figure 1. Normally, these cells produce the chemical dopamine, which allows for smooth, coordinated function of the body’s muscles and movement.1-3 The symptoms of PD appear when approximately 80% of the dopamineproducing cells are damaged.3 After Alzheimer’s disease, PD is the second most common neurodegenerative condition affecting an estimated 3% of Americans aged 65 and older.4,5 PD, which makes up approximately 80% of cases of parkinsonism, affects 4 million people worldwide.1,2 The brain disorder is more common in men, with a male-to-female ratio of 3:2.2 As prevalence and incidence of PD increase with age, the number of individuals afflicted is expected to rise considerably.
REQUIP XL is an oral dopamine agonist medication for Parkinson’s disease and had demonstrated significant improvement in the symptoms of Parkinson’s disease.
The Role of Immune Function in the Changing Landscape of RRMS Therapies
Gastroesophageal reflux disease (GERD) is an important
managed care health concern because it is one of the most common gastrointestinal (GI) disorders in the United
States. GERD affects nearly 18.6 million Americans, according to a national healthcare database analysis.
Parkinson’s disease (PD) is a progressive
and disabling neurologic disorder. The disease is the most prevalent type of parkinsonism, a clinical syndrome caused by lesions in the basal ganglia, predominantly in the substantia nigra, which produces deficits in motor behavior.







